Epidemiology of osteochimionecrosis of the jaws in France, update of data since 2015

Autor: Legendre, Q, Faillie, Jl, Lapeyrie, P, Tramini, P, Maladiere, E, Torres, JH, Lallemant, B

Publikováno v: In Journal of Stomatology oral and Maxillofacial Surgery October 2022 123(5):e448-e453

Pioglitazone and bladder cancer.

Autor: Hillaire-Buys D (AUTHOR), Faillie JL (AUTHOR), Montastruc JL (AUTHOR)

Publikováno v: Lancet. 10/29/2011, Vol. 378 Issue 9802, p1543-1545. 4p.

Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.

Autor: Soeiro T; Service de pharmacologie clinique et pharmacosurveillance, AP-HM, 270, boulevard de Sainte-Marguerite, 13009 Marseille, France; Aix-Marseille université, Inserm U1106, 13009 Marseille, France. Electronic address: thomas.soeiro@ap-hm.fr., Allouchery M; Service de pharmacologie clinique et vigilances, CHU de Poitiers, 86000 Poitiers, France; ProDiCeT, CHU de Poitiers, université de Poitiers, 86000 Poitiers, France., Bene J; Centre régional de pharmacovigilance, CHU de Lille, 59000 Lille, France., Bezin J; Équipe AHeaD, CHU de Bordeaux, service de pharmacologie clinique, BPH, université de Bordeaux, Inserm U1219, 33000 Bordeaux, France., Dolladille C; Service de pharmacologie, unité de pharmacoépidémiologie, ANTICIPE, université Caen-Normandie, Inserm U1086, 14000 Caen, France., Faillie JL; Service de pharmacologie médicale et toxicologie, CHU de Montpellier, 34000 Montpellier, France; IDESP, université de Montpellier, Inserm UMR UA11, 34000 Montpellier, France., Grimaldi L; Service de pharmacologie, GHU Paris-Saclay, hôpital Bicêtre, AP-HP, 94275 Le Kremlin-Bicêtre, France; Équipe échappement aux anti-infectieux et pharmacoépidémiologie, Inserm U1018, CESP, 94800 Villejuif, France., Kaguelidou F; GHU Nord, hôpital Robert-Debré, Inserm CIC1426, AP-HP, 75019 Paris, France; URP 7323, université Paris Cité, 75006 Paris, France., Khouri C; Centre régional de pharmacovigilance, CHU Grenoble-Alpes, 38000 Grenoble, France; Laboratoire HP2, université Grenoble-Alpes, Inserm U1300, 38000 Grenoble, France., Lafaurie M; Service de pharmacologie médicale et clinique, CHU de Toulouse, 31000 Toulouse, France; Équipe PEPSS, CHU de Toulouse, Inserm CIC1436, 31000 Toulouse, France., Largeau B; Service de pharmacologie médicale et pharmacosurveillance, CHRU de Tours, 37000 Tours, France; Inserm U1327, ISCHEMIA, université de Tours, 37000 Tours, France., Montastruc F; Service de pharmacologie médicale et clinique, CHU de Toulouse, 31000 Toulouse, France; Équipe PEPSS, CHU de Toulouse, Inserm CIC1436, 31000 Toulouse, France., Morin L; CESP, HiDiBiostat, Inserm U1018, 94800 Villejuif, France., Scailteux LM; EHESP, Inserm U1085, Irset, CHU Rennes, université Rennes, 35000 Rennes, France., Pariente A; Équipe AHeaD, CHU de Bordeaux, service de pharmacologie clinique, BPH, université de Bordeaux, Inserm U1219, 33000 Bordeaux, France.

Publikováno v: Therapie [Therapie] 2024 Dec 14. Date of Electronic Publication: 2024 Dec 14.

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.

Autor: Hountondji L; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Faure S; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Palassin P; Department of Medical Pharmacology and Toxicology, Lapeyronie Hospital, Montpellier University Hospital, Montpellier, France., Viel PWD; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier University Hospital, Montpellier, France.; Internal Medicine, Beziers Hospital, Béziers, France., Dupuy M; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Larrey D; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; REFHEPS, Montpellier, France., Lamoureux A; Department of Dermatology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Coustal C; Internal Medicine & Immuno-Oncology (MedI2O), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Pureur D; Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Lesage C; Department of Dermatology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Assenat É; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; Montpellier University, Montpellier, France., Rivière B; Department of Pathology, Montpellier University Hospital, University of Montpellier, Montpellier, France., Faillie JL; Department of Medical Pharmacology and Toxicology, Lapeyronie Hospital, Montpellier University Hospital, Montpellier, France.; Montpellier University, Montpellier, France., Quantin X; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier University Hospital, Montpellier, France., Pageaux GP; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; Montpellier University, Montpellier, France., Maria ATJ; Internal Medicine & Immuno-Oncology (MedI2O), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; Montpellier University, Montpellier, France.; Internal Medicine & Immuno-Oncology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France., Meunier L; Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.; REFHEPS, Montpellier, France.; Internal Medicine & Immuno-Oncology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Dec; Vol. 60 (11-12), pp. 1561-1572. Date of Electronic Publication: 2024 Sep 24.

Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.

Autor: Bénard-Laribière A; Université de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France anne.benard@u-bordeaux.fr., Pambrun E; Université de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France., Kouzan S; Pulmonary Department, Centre Hospitalier Metropole Savoie, Chambery, France., Faillie JL; CHU Montpellier, Service de Pharmacologie Médicale et Toxicologie, Montpellier, France.; Université de Montpellier, INSERM, Institut Desbrest d'Épidémiologie et de Santé Publique, Montpellier, France., Bezin J; Université de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France.; CHU de Bordeaux, Clinical Pharmacology Unit, INSERM, U1219, Bordeaux, France., Pariente A; Université de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France.; CHU de Bordeaux, Clinical Pharmacology Unit, INSERM, U1219, Bordeaux, France.

Publikováno v: Thorax [Thorax] 2024 Oct 11. Date of Electronic Publication: 2024 Oct 11.